Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Adebrelimab plus Apatinib; Drug: Adebrelimab plus Bevacizumab; Drug: Camrelizumab plus Apatinib Sponsors: Peking University Cancer Hospital& Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials